Long-term management of patients with metastatic renal cell carcinoma on targeted agents

Expert Review of Anticancer Therapy

Volumn 10, Issue 12, 2010, Pages 1883-1889

  Jonasch, Eric ^a   Pagliaro, Lance C ^a   Tannir, Nizar M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cancer survivorship; renal cell carcinoma; targeted therapy; therapy complications

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CLOBETASOL; COLESTYRAMINE; CORTICOSTEROID; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENOXYLATE; ERLOTINIB; EVEROLIMUS; LIDOCAINE; LOPERAMIDE; OPIATE; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VERAPAMIL;

ACTINIC KERATOSIS; ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; BLOATING; CARDIOTOXICITY; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG INHIBITION; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; METABOLIC SYNDROME X; MUCOSAL DISEASE; NAUSEA; NEPHRECTOMY; NEPHROTIC SYNDROME; PNEUMONIA; PROTEINURIA; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SKIN CARCINOMA; STOMATITIS; THYROID FUNCTION TEST; VEIN THROMBOSIS; VENOPUS THROMBOSIS; VOMITING; WOUND HEALING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY; QUALITY OF LIFE; REMISSION INDUCTION; TIME FACTORS;

EID: 78649647055     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.195     Document Type: Review

References (46)

1. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon a-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007).
2. Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind Phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as frst-line therapy in metastatic renal cell carcinoma. J. Clin. Oncol. 25(Suppl. 18) (2007) (Abstract 3).
3. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007). (Pubitemid 46089672)
4. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon a compared with interferon a monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26(33), 5422-5428 (2008).
5. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007). (Pubitemid 46849157)
6. Motzer RJ, Escudier B, Oudard S et al. Effcacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
7. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
8. Mickisch GH, Garin A, Van Poppel H, De Prijck L, Sylvester R. Radical nephrectomy plus interferon-a-based immunotherapy compared with interferon a alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286), 966-970 (2001).
9. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon a-2b compared with interferon a-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345(23), 1655-1659 (2001).
10. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
11. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-a as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002).
12. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27(34), 5794-5799 (2009).
13. Van Der Veldt AA, Meijerink MR, Van Den Eertwegh AJ et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14(8), 2431-2436 (2008).
14. Cowey CL, Amin C, Pruthi RS et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 28(9), 1502-1507 (2010).
15. Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(25), 4076-4081 (2009).
16. Shuch B, Riggs SB, Larochelle JC et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 102(6), 692-696 (2008).
17. Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181(2), 518-523 (2009).
18. Margulis V, Matin SF, Tannir N et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180(1), 94-98 (2008).
19. Thompson RH, Boorjian SA, Lohse CM et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J. Urol. 179(2), 468-471 (2008).
20. Kavolius JP, Mastorakos DP, Pavlovich C et al. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 16(6), 2261-2266 (1998).
21. Friedel G, Hurtgen M, Penzenstadler M, Kyriss T, Toomes H. Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res. 19(2C), 1593-1596 (1999).
22. Golimbu M, Joshi P, Sperber A et al. Renal cell carcinoma: survival and prognostic factors. Urology 27(4), 291-301 (1986).
23. Kierney PC, Van Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann. Surg. Oncol. 1(4), 345-352 (1994).
24. Van Der Poel HG, Roukema JA, Horenblas S, Van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur. Urol. 35(3), 197-203 (1999).
25. Daliani DD, Tannir NM, Papandreou CN et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 104(4), 456-460 (2009).
26. Albiges L, Oudard S, Negrier S et al. Complete remission with TKI in renal cell carcinomas: experience in 65 patients of the French Kidney Cancer Group. J. Clin. Oncol. 28(Suppl. 15) (2010) (Abstract 4600).
27. Johannsen M, Staehler M, Ohlmann CH et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann. Oncol. DOI: 10.1093/annonc/mdq437 (2010) (Epub ahead of print).
28. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 6(8), 465-477 (2009).
29. Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr. Opin. Support. Palliat. Care 3(3), 170-179 (2009).
30. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77(5), 257-271 (2009).
31. Houk BE, Bello CL, Poland B et al. Relationship between exposure to sunitinib and effcacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. 66(2), 357-371 (2010).
32. Ilias-Khan NA, Khakoo AY, Tannir NM. A clinical and biological profle to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib. J. Clin. Oncol. 28(15 Suppl.) (2010) (Abstract 4601).
33. Rini BI, Cohen DP, Lu D et al. Hypertension (HTN) as a biomarker of effcacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Presented at: The American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
34. Atkinson BJ, Tannir NM, Jonasch E. Schedule modifcations and treatment outcomes for sunitinib-related adverse events. J. Clin. Oncol. 28(Suppl.) (2010) (Abstract e15115).
35. Di Lorenzo G, Autorino R, Bruni G et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann. Oncol. 20(9), 1535-1542 (2009).
36. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604), 2011-2019 (2007).
37. Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112(11), 2500-2508 (2008).
38. Constantiner M, Sehgal AR, Humbert L et al. A dipstick protein and specifc gravity algorithm accurately predicts pathological proteinuria. Am. J. Kidney Dis. 45(5), 833-841 (2005).
39. Atkinson BJ, Wilhelm KL, Khakoo AY, Tannir NM, Jonasch E. A retrospective evaluation of antiangiogenic therapy-induced hypertension in metastatic renal cell carcinoma. J. Clin. Oncol. 28(Suppl.) (2010) (Abstract e15047).
40. Dubauskas Z, Kunishige J, Prieto VG et al. Cutaneous squamous cell carcinoma and infammation of actinic keratoses associated with sorafenib. Clin. Genitourin. Cancer 7(1), 20-23 (2009).
41. Arnault JP, Wechsler J, Escudier B et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 27(23), e59-e61 (2009).
42. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 10(10), 967-974 (2009).
43. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 28(13), 2280-2285 (2010).
44. Rini B I, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 99(1), 81-83 (2007).
45. Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol. 19(2), 265-268 (2008). (Pubitemid 351201706)
46. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profle and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann. Oncol. 19(8), 1387-1392 (2008).